Navigation Links
Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Date:11/13/2008

CORONA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for a 6-month formulation of TRELSTAR(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking marketing approval of this TRELSTAR(R) formulation for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on its application in the third quarter 2009.

The sustained-release formulation of TRELSTAR(R) is designed to suppress the production of testosterone in men with advanced prostate cancer over 6 months. Prostate cancer growth is regulated in part by the level and activity of testosterone.

"This filing reflects Watson's commitment to urology and to making a difference in the lives of men living with prostate cancer," said Paul Bisaro, Watson's President and Chief Executive Officer. "This new longer duration TRELSTAR(R) formulation requires only one injection every 24 weeks, and showed comparable efficacy and safety with our marketed TRELSTAR(R) 1 and 3-month formulations. The TRELSTAR(R) 6-month formulation should be a welcome alternative for men and their physicians and will be a significant addition to our expanding urology portfolio."

About TRELSTAR(R)

TRELSTAR(R), developed by Debiopharm Group, a Swiss biopharmaceutical development specialist, and marketed by Watson Pharma, Inc., is a synthetic hormone known as a luteinizing hormone releasing hormone (LHRH) agonist, which suppresses the production of testosterone in the testicles. The growth of the prostate is reg
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine news :

1. Watson Pharmaceuticals Reports Third Quarter 2008 Results
2. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
3. Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds
4. Watson Wyatt Identifies Trends for Benefits Open Enrollment Season
5. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
6. Watson Announces Limited Recall of Fentanyl Transdermal System
7. Watson Launches Omeprazole Delayed-Release Capsules, 40MG
8. Chantix Blamed for Suicide in Lawsuit Against Pfizer Filed by Cory Watson Crowder & DeGaris
9. Watson Launches Generic MARINOL(R) Capsules
10. Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
11. Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...Researchers at Ben-Gurion University of the Negev ... skin tumors, including melanomas that aren,t visi...the OSPI instrument (Optical Spectro-Polarimetric ...e never been seen before - including melanoma in p...ns and were awaiting surgery for their removal. Th...
(Date:11/24/2009)...Mid-Winter Meetings Jan. 27Feb. 2, 2010, at the Al...his year, SNM joins its annual Mid-Winter Educatio...cational Symposium of the American College of Nucl...r Imaging Summit and the Clinical Trials Network C...icipants an outstanding range of scientific conten...
(Date:11/24/2009)...sed sevenfold, study finds, , , TUESDAY...c-resistant infections normally found in the commu...tpatients, raising the risk that inpatients could ... to 2006, researchers found a sevenfold increase i...sistant Staphylococcus aureus (MRSA) infections....
(Date:11/24/2009)...ice to be coupled with Stem Cell Therapy. , ...24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB... a manufacturer of lasers regarding the developmen...ed by Entest and used in conjunction with several ...ntest. These therapies are aimed at increasing eff...
(Date:11/24/2009)...o Get a Leg Up From the American Podiatric Medical...Md. (Vocus) November 24, 2009 -- The average perso... that number dramatically increases during the hol...continue making their holiday travel plans, it&rsq...runt of aches and pains while on the road. , , , ...
Breaking Medicine News(10 mins):Health News:New device enables early detection of cancerous skin tumors -- Ben Gurion U. 2Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Keep Holiday Travel Foot-Friendly 2Health News:Keep Holiday Travel Foot-Friendly 3
...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...
...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...
...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...
...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...
...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...
... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...
Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
(Date:11/24/2009)...,Nov.24/PRNewswire-Asia/--HuifengBio-Pharmaceutica...eveloperandproducer,ofplantextractsandpharmaceutic...landfoodproductioninXi,an,China,todayreportedthati...revenues. , RevenuesforthequarterendedSept.30...om$3,534,623forthesamequarterin2008.Netincome,amou...
(Date:11/24/2009)...OOD,Calif.,Nov.24/PRNewswire-FirstCall/--IPCTheHos...alhospitalistphysiciangrouppracticecompany,announc...t,wasnamedby ACPHospitalist asoneofthe2009TopTenHo...2009issueofthemagazine. ,, Dr.Vaidyanhasbeenapr...vesasdirectorofhospitalmedicineatSt.Mary,sHealthCe...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--ZimmerHoldings,Inc....atinginthe21stAnnualPiperJaffrayHealthCareConferen...ternTime. ,, Alivewebcastofthepresentationcanbe...://investor.zimmer.com .Thewebcastwillbearchivedfo...any ,, Foundedin1927andheadquarteredinWarsaw,I...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 1Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 3Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 1Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 2Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 4Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 5Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 6
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
Schepens Depressor 8.0mm Wide Tip Thimble Size 12
Yavitz Flap Cover
Chayett Drainage Ring
Weck-Cel Points
Medicine Products: